| Literature DB >> 33007416 |
Yu-Qiong He1, Can-Can Zhou2, Lu-Yao Yu1, Liang Wang1, Jiu-Ling Deng1, Yu-Long Tao3, Feng Zhang4, Wan-Sheng Chen5.
Abstract
Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS) as common life-threatening lung diseases with high mortality rates are mostly associated with acute and severe inflammation in lungs. With increasing in-depth studies of ALI/ARDS, significant breakthroughs have been made, however, there are still no effective pharmacological therapies for treatment of ALI/ARDS. Especially, the novel coronavirus pneumonia (COVID-19) is ravaging the globe, and causes severe respiratory distress syndrome. Therefore, developing new drugs for therapy of ALI/ARDS is in great demand, which might also be helpful for treatment of COVID-19. Natural compounds have always inspired drug development, and numerous natural products have shown potential therapeutic effects on ALI/ARDS. Therefore, this review focuses on the potential therapeutic effects of natural compounds on ALI and the underlying mechanisms. Overall, the review discusses 159 compounds and summarizes more than 400 references to present the protective effects of natural compounds against ALI and the underlying mechanism.Entities:
Keywords: Acute lung injury; Acute respiratory distress syndrome; Baicalin (PubChem CID: 64982); Chemical structures; Curcumin (PubChem CID: 969516); Emodin (PubChem CID: 3220); Hydroxysafflor yellow A (PubChem CID: 6443665); Kaempferol (PubChem CID: 5280863); Luteolin (PubChem CID: 5280445); Mechanisms; Natural compounds; Osthole (PubChem CID: 10228); Quercetin (PubChem CID: 5280343); Resveratrol (PubChem CID: 445154); Tanshinone IIA (PubChem CID: 164676)
Year: 2020 PMID： 33007416 PMCID： PMC7522693 DOI： 10.1016/j.phrs.2020.105224
Source DB: PubMed Journal: Pharmacol Res ISSN： 1043-6618 Impact factor: 7.658